---
id: stenotrophomonas-maltophilia_066
category: organisms
tags: [stenotrophomonas-maltophilia, TMP-SMX, levofloxacin, minocycline, cefiderocol, MDR]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Stenotrophomonas maltophilia

**Q:** What are the clinical characteristics, risk factors, and treatment approach for Stenotrophomonas maltophilia infections?

**A:**

**Microbiology:**
- **Gram-negative bacillus** (non-fermenter)
- **Intrinsically multidrug-resistant** (MDR)
- Environmental organism (water, plants, hospital equipment)
- Biofilm producer

**Intrinsic Resistance Mechanisms:**
- **β-lactamases:** L1 (metallo-β-lactamase), L2 (cephalosporinase)
- **Efflux pumps:** Fluoroquinolone, aminoglycoside, TMP-SMX resistance
- **Impermeability:** Low outer membrane permeability

**Result:** Resistant to most β-lactams (including carbapenems), aminoglycosides, polymyxins

---

**Epidemiology & Risk Factors:**

**Patient Risk Factors:**
- **Prolonged hospitalization** (ICU stay)
- **Broad-spectrum antibiotic exposure** (especially carbapenems)
- **Mechanical ventilation**
- **Central venous catheters**
- **Immunosuppression:** Malignancy, transplant, neutropenia
- **Cystic fibrosis**
- **Prior Pseudomonas infection** (ecological niche replacement)

**Key Point:** S. maltophilia emerges after carbapenem therapy (ecological pressure)

---

**Clinical Syndromes:**

**1. Pneumonia/VAP (Most Common):**
- **Hospital-acquired pneumonia** (HAP)
- **Ventilator-associated pneumonia** (VAP)
- Difficulty distinguishing colonization from infection

**2. Bacteremia/CLABSI:**
- Central line-associated bloodstream infection
- High mortality (20-40%)

**3. Urinary Tract Infection:**
- Often catheter-associated

**4. Skin/Soft Tissue:**
- Cellulitis, wound infections (rare)

**5. Cystic Fibrosis Lung Infection:**
- Chronic colonization/infection
- More resistant strains

**Colonization vs Infection:**
- **Common colonizer** (respiratory tract, urine)
- Positive culture does NOT always = true infection
- Consider: Clinical context, inflammatory markers, imaging

---

**Diagnosis:**

**Culture:**
- Routine media (MacConkey, blood agar)
- Slow growth (48-72h)
- Characteristic colonies: Lavender-green pigment on blood agar

**Susceptibility Testing:**
- **MUST test susceptibility** (resistance varies)
- **Updated CLSI breakpoints** (2024): More stringent for TMP-SMX, levofloxacin

---

**Treatment:**

**Key Principles:**
- **2024 IDSA Guidelines recommend combination therapy** (two active agents)
- Monotherapy concerns: Emergence of resistance during treatment
- Source control (remove catheter if CLABSI)

**1. First-Line Antibiotics:**

**Preferred (Choose 2 for Combination):**

| **Antibiotic** | **Dosing** | **Susceptibility** | **Notes** |
|----------------|------------|-------------------|-----------|
| **TMP-SMX** (preferred) | 5 mg/kg (TMP component) IV q6-8h | 79-96% | First-line agent |
| **Levofloxacin** | 750 mg IV/PO q24h | ~86% (but ↑ resistance) | Combination preferred |
| **Minocycline** | 100 mg IV/PO q12h | 98-99% | Excellent for resistant cases |

**Second-Line (Newer Agents):**

| **Antibiotic** | **Dosing** | **Susceptibility** | **Notes** |
|----------------|------------|-------------------|-----------|
| **Cefiderocol** | 2g IV q8h (3h infusion) | High | Effective even if TMP-SMX/levo resistant |
| **Ceftazidime-avibactam + aztreonam** | CAZ-AVI 2.5g IV q8h + aztreonam 2g IV q8h | Variable | Investigational combination |
| **Ticarcillin-clavulanate** | 3.1g IV q4h | ~70% | Less available |

**Other Options:**
- **Tigecycline:** 100 mg IV x1, then 50 mg IV q12h (bacteriostatic, avoid for bacteremia)
- **Chloramphenicol:** 50-100 mg/kg/day IV divided q6h (rarely used, toxicity)

---

**2024 IDSA Guidance:**

**Combination Therapy (Preferred):**
- **TMP-SMX + minocycline** OR
- **TMP-SMX + levofloxacin** OR
- **Levofloxacin + minocycline** OR
- **Cefiderocol + one of the above**

**OR**

- **Ceftazidime-avibactam + aztreonam** (if above agents unavailable)

**Rationale:**
- Synergistic killing
- Prevent resistance emergence
- Improved outcomes (especially in bacteremia)

**Monotherapy Concerns:**
- **Levofloxacin monotherapy:** High rate of resistance emergence (avoid)
- **TMP-SMX monotherapy:** Acceptable if susceptible and not severe infection

---

**2. Treatment by Syndrome:**

**Pneumonia/VAP:**
- Combination therapy (TMP-SMX + levofloxacin OR TMP-SMX + minocycline)
- Duration: 7-14 days

**Bacteremia/CLABSI:**
- **Remove catheter** (essential)
- Combination therapy (TMP-SMX + minocycline preferred)
- Duration: 14 days (if catheter removed, uncomplicated)

**Cystic Fibrosis Exacerbation:**
- TMP-SMX (if susceptible)
- Levofloxacin (alternative)
- May require prolonged therapy

---

**Resistance Patterns (2024):**

**Global Resistance Rates:**
- **TMP-SMX:** 9.2% resistance (but ↑ in CF patients: 10-40%)
- **Levofloxacin:** 14.4% resistance
- **Minocycline:** 1.4% resistance (most active)
- **Tigecycline:** Variable (22-78% in levofloxacin-resistant strains)
- **Colistin:** 40-60% resistance (ineffective)

**Multidrug-Resistant (MDR) S. maltophilia:**
- **Levofloxacin-resistant strains:** Often resistant to TMP-SMX (99%), tigecycline (78%)
- **Minocycline and cefiderocol retain activity**

---

**3. Special Considerations:**

**Cystic Fibrosis:**
- Higher resistance rates (prior antibiotic exposure)
- Consider minocycline if TMP-SMX/levofloxacin resistant
- Chronic suppressive therapy sometimes needed

**Neutropenic Patients:**
- Higher mortality (30-60%)
- Combination therapy essential
- Avoid tigecycline (bacteriostatic)

**Polymicrobial Infections:**
- S. maltophilia often co-isolated with Pseudomonas, Acinetobacter
- Ensure therapy covers all pathogens

---

**Prognosis:**

**Mortality:**
- Bacteremia: 20-40%
- Pneumonia: 10-30%
- Higher in neutropenic patients, ICU patients

**Predictors of Mortality:**
- Inappropriate empiric therapy
- Delayed source control
- Neutropenia
- Severe sepsis/shock

---

**Comparison: S. maltophilia vs Pseudomonas vs Acinetobacter**

| **Feature** | **S. maltophilia** | **Pseudomonas** | **Acinetobacter (CRAB)** |
|-------------|-------------------|-----------------|--------------------------|
| **Intrinsic resistance** | ✅ Extensive (carbapenems, polymyxins) | Limited | ✅ Extensive (if CRAB) |
| **First-line Rx** | **TMP-SMX** | Anti-pseudomonal β-lactam | Colistin, ampicillin-sulbactam, cefiderocol |
| **Carbapenem** | ❌ Resistant (MBL) | Usually susceptible (if not CRE) | ❌ Resistant (if CRAB) |
| **Polymyxin** | ❌ Resistant | Susceptible | Susceptible |
| **Combination Rx** | ✅ Recommended (IDSA 2024) | For severe/resistant | ✅ Recommended |

---

**Mnemonic: "STENOTROPHOMONAS = Super Tough, Emerges with carbaNeMs, TMP-SMX Preferred, HAs intrinsic Resistance"**
- **S**uper tough (MDR)
- **T**MP-SMX preferred first-line
- **E**merges with carbapenem use
- **N**eutropenia = high mortality
- **M**inocycline excellent (1.4% resistance)

**Mnemonic: "TMP-SMX + Minocycline = Magic Combo"**
- **T**MP-SMX first-line
- **M**inocycline excellent alternative (low resistance)
- Combination = **Magic** (IDSA 2024 guidance)

**Clinical Pearls:**
- **TMP-SMX = first-line** (79-96% susceptible)
- **Minocycline = best agent** for resistant strains (98-99% susceptible, only 1.4% resistance)
- **Combination therapy recommended** (IDSA 2024) - prevents resistance emergence
- **Emerges after carbapenem therapy** (ecological niche after Pseudomonas suppressed)
- **Intrinsically resistant to carbapenems** (MBL L1) and polymyxins
- **Colonization common** → distinguish from true infection (clinical context)
- **Cefiderocol active** even against TMP-SMX/levofloxacin-resistant strains
- **Remove catheters** (if CLABSI) - essential for cure
- **Levofloxacin monotherapy contraindicated** (resistance emergence)
- CF patients have higher resistance rates (10-40% to TMP-SMX)
- **Updated CLSI breakpoints 2024** → more stringent susceptibility criteria

**Media:** None

**Sources:** [IDSA 2024 - AMR guidance], [PMC 2021 - Antimicrobial treatment strategies], [Medscape 2024 - S. maltophilia medication], [OFI 2022 - TMP-SMX vs levofloxacin comparative effectiveness], [PubMed 2023 - Global resistance meta-analysis], [ScienceDirect 2024 - Multicentre cohort TMP-SMX vs levofloxacin], [MDPI 2024 - PK/PD optimization], [CLSI 2024 - Updated breakpoints]
